CellaVision AB (CEVI) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

14.71 k

Shareholding (Dec 2016)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROE of 19.18%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 15.75

Poor long term growth as Operating profit has grown by an annual rate 12.46% of over the last 5 years

Flat results in Jun 25

With ROE of 18.37%, it has a very expensive valuation with a 5.22 Price to Book Value

Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 3,826 Million (Small Cap)

P/E

28.00

Industry P/E

Dividend Yield

0.01%

Debt Equity

-0.15

Return on Equity

17.78%

Price to Book

4.49

Revenue and Profits:

Net Sales:

191 Million

(Quarterly Results - Jun 2025)

Net Profit:

38 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

433.79%

6 Months

433.79%

1 Year

433.79%

2 Years

697.97%

3 Years

751.6%

4 Years

2281.82%

5 Years

2520.0%

CellaVision AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

8.83%

EBIT Growth (5y)

12.46%

EBIT to Interest (avg)

15.75

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.19

Sales to Capital Employed (avg)

0.87

Tax Ratio

20.41%

Dividend Payout Ratio

42.37%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

26.30%

ROE (avg)

19.18%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.22

EV to EBIT

21.16

EV to EBITDA

17.85

EV to Capital Employed

5.98

EV to Sales

5.55

PEG Ratio

6.74

Dividend Yield

0.01%

ROCE (Latest)

28.26%

ROE (Latest)

18.37%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2016

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 1.86% vs 10.67% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -2.34% vs 10.95% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "191.30",
          "val2": "187.80",
          "chgp": "1.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "59.60",
          "val2": "59.70",
          "chgp": "-0.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "2.60",
          "chgp": "57.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "37.60",
          "val2": "38.50",
          "chgp": "-2.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "263.00%",
          "val2": "261.50%",
          "chgp": "0.15%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.78% vs 5.94% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.98% vs 10.14% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "723.20",
          "val2": "677.30",
          "chgp": "6.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "218.70",
          "val2": "206.80",
          "chgp": "5.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "3.30",
          "chgp": "-42.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "140.70",
          "val2": "130.30",
          "chgp": "7.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "245.70%",
          "val2": "246.60%",
          "chgp": "-0.09%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

191.30

187.80

1.86%

Operating Profit (PBDIT) excl Other Income

59.60

59.70

-0.17%

Interest

4.10

2.60

57.69%

Exceptional Items

0.00

Consolidate Net Profit

37.60

38.50

-2.34%

Operating Profit Margin (Excl OI)

263.00%

261.50%

0.15%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 1.86% vs 10.67% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -2.34% vs 10.95% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

723.20

677.30

6.78%

Operating Profit (PBDIT) excl Other Income

218.70

206.80

5.75%

Interest

1.90

3.30

-42.42%

Exceptional Items

0.00

Consolidate Net Profit

140.70

130.30

7.98%

Operating Profit Margin (Excl OI)

245.70%

246.60%

-0.09%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 6.78% vs 5.94% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.98% vs 10.14% in Dec 2023

All Annual Results

Company CV

About CellaVision AB

CellaVision AB

Pharmaceuticals & Biotechnology

CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

Company Coordinates

Company Details

Mobilvagen 12 , LUND None : 223 62

Tel: 46 46 460160046 46 4601652

http://www.cellavision.com

Registrar Details